

Having trouble viewing this email? [Click here](#)



As the summer comes to an end, WorldCare remains steadfast in our mission of improving your healthcare outcomes by connecting you and your treating physician to the leading medical experts at the top-ranked hospitals in the United States, which comprise The WorldCare Consortium™. We also provide you with this free, quarterly publication to keep you informed of the latest updates from these hospitals and from us. We hope you find this issue informative and helpful.

Latest News Stories from WorldCare

- [WorldCare International; Second Opinions and Reduced Medical Costs](#)
- [Healthier Workplace More Important Than Ever - *Benefits & Pensions Monitor*](#)
- [1.800MD Introduces NaviGo Health as a Premier Health Care-Savings Tool](#)

Request service.



Source: [Massachusetts General Hospital](#)

The average time it takes for a person entering a hospital's emergency room to reach an operating room is thirty-six minutes. For someone with a noncompressible abdominal hemorrhage, a serious, life-threatening trauma, that means 36 minutes of blood loss.

For 10 years, Dr. David King, MD, of [WorldCare Consortium™](#) member [Massachusetts General Hospital](#) and a team of engineers have been working to develop and produce ResQFoam, a self-expanding polyurethane trauma foam that has been approved by the FDA for use in a clinical trial. ResQFoam is injected into the body, quickly expanding to fill the abdominal cavity and applying pressure that may stabilize the patient. The foam temporarily stops bleeding in patients with noncompressible abdominal hemorrhage, which until now has only been able to be stopped through surgery.

[Read the full story here.](#)

"From the start of the process to receiving the report, this process went very smoothly. I am grateful to have had this opportunity to have my file reviewed by the WorldCare Team. This booklet has certainly given me a piece of mind on what is going on within my body. Thank you for the prompt, expertise service provided by the WorldCare Team."

- Elizabeth, WorldCare member

Massachusetts General Hospital Research Institute by the Numbers

Source: [Massachusetts General Hospital](#)

\$912 million

research budget in 2017.

30 departments

centers and institutions where
research occurs across the hospital.

8,500 people


included in the research community.

85,000 patients

have consented to have blood samples &
health histories added to the Partners Biobank
at MGH, allowing further understanding about
the genetic basis of disease.

Discover how a MSO from WorldCare changed Courtney's life.

[Watch video.](#)



Source: [Mayo Clinic](#)

A research team led by a geneticist at [WorldCare Consortium™](#) member [Mayo Clinic](#) has identified specific genes associated with an increased risk for developing triple-negative breast cancer. The research, led by Fergus Couch, Ph.D., was published in the *Journal of the National Cancer Institute*.

The research team performed genetic testing on 10,901 patients with triple-negative breast cancer from two studies. They tested 21 cancer predisposition genes in 8,753 patients and 17 genes in the remaining 2,148 patients, finding that alternations in BARD1, BRCA1, BRCA2, PALB2 and RAD51D genes were associated with a high risk for triple-negative breast cancer and a greater than 20 percent lifetime risk for overall breast cancer among Caucasians. The researchers also observed a similar trend among African-Americans, and found that mutations in the BRIP1 and RAD51C genes were linked to a more moderate risk of triple-negative breast cancer.

[Read the full story here.](#)

Have you been diagnosed with cancer and want a medical second opinion to ensure proper diagnosis and receive optimal treatment plan recommendations?

Contact us today.

Breast Cancer in Women: Know the Subtype

Source: [National Cancer Institute](#)

BREAST CANCER IN WOMEN: KNOW THE SUBTYPE

It's important for guiding treatment and predicting survival.



KNOW THE SCIENCE



HR = Hormone receptor

HR+ means tumor cells have receptors for the hormones estrogen or progesterone, which can promote the growth of HR+ tumors. Hormone therapies like tamoxifen can be used to treat HR+ tumors.

HER2 = Human epidermal growth factor receptor

HER2+ means tumor cells overexpress (make high levels of) a protein, called HER2/neu, which has been shown to be associated with certain aggressive types of breast cancer. Trastuzumab and some other therapies can target cells that overexpress HER2.

HR+/HER2-> aka "Luminal A"

73% of all breast cancer cases

- Best prognosis
- Most common subtype for every race, age, and poverty level



HR-/HER2-> aka "Triple Negative"

13% of all breast cancer cases

- Worst prognosis
- Non-Hispanic blacks have highest rate of this subtype at every age and poverty level



HR+/HER2+> aka "Luminal B"

10% of all breast cancer cases

- Little geographic variation by state



HR-/HER2+> aka "HER2-enriched"

5% of all breast cancer cases

- Lowest rates for all races and ethnicities

cancer.gov

Source: Special section of the Annual Report to the Nation on the Status of Cancer, 1975-2011.

**Discover the WorldCare Difference, why our MSOs
have been trusted for over 25 years.**

Subscribe to our blog.

**"Thank you, your opinion is invaluable for our peace of mind."
- Ken, WorldCare Member**

See what's happening on our social sites:



WorldCare International, Inc. | marketing@worldcare.com | www.worldcare.com

Worldcare International, 7 Bulfinch Place, Suite 301, Boston, MA 02127

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by pcarmichael@worldcare.com in collaboration with



Try it free today